Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial - sprookjes - yvandenbroek - TriplyDB

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial

http://www.wikidata.org/entity/Q28650557

about

Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.A systems approach to vaccine decision making.

P2860

Q38631381-BB8F344D-5FE0-406B-A7DA-24A059464A4B Q48031367-AE73481A-4EE7-40F0-A19D-1B359A8C23CB

P2860

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial

http://www.wikidata.org/entity/Q28650557

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Immunogenicity of reduced dose ...... el randomised controlled trial

@ast

Immunogenicity of reduced dose ...... el randomised controlled trial

@en

Immunogenicity of reduced dose ...... el randomised controlled trial

@nl

type

label

Immunogenicity of reduced dose ...... el randomised controlled trial

@ast

Immunogenicity of reduced dose ...... el randomised controlled trial

@en

Immunogenicity of reduced dose ...... el randomised controlled trial

@nl

prefLabel

Immunogenicity of reduced dose ...... el randomised controlled trial

@ast

Immunogenicity of reduced dose ...... el randomised controlled trial

@en

Immunogenicity of reduced dose ...... el randomised controlled trial

@nl

P1433

Q28650557-00B29725-DAE3-48D6-8A2B-A3181F89287C

P1476

Q28650557-CF5B204E-B0EE-46FE-A761-67726BEC6900

P2093

Q28650557-00CF4DED-34E5-4135-A596-06719B925BFF

Q28650557-02000171-CAB8-49CC-864B-C49E68C1F467

Q28650557-1B7CB163-3552-49D9-87C3-6D110CC58BB0

Q28650557-2176A97D-A2BE-4D79-8A38-93D5F9CB713A

Q28650557-309A1564-8728-45A9-9797-E46B51A4ED62

Q28650557-5592DB45-1679-4DE3-9D7A-08643AB27AE5

Q28650557-C7D0E4CA-78FB-4C25-919A-628FFDBEAC9E

Q28650557-DD6E32CD-7EB6-41A2-8B2F-26FEBAAABE31

Q28650557-F3A744F8-5040-4D71-9935-8E7D06669453

Q28650557-F621B95F-93CE-4E87-B426-FF7D416BF883

P2860

Q28650557-05C2EEDA-5A27-4E7D-9542-08ADDFBD1B03

Q28650557-071F8E39-8EC5-4172-B5FB-8928E2A54B4B

Q28650557-0BA72483-338A-4A82-9CC4-393D2D7814C1

Q28650557-0BF547B7-77A3-4CE2-BD70-C604BA561E34

Q28650557-16B7C6AC-6C34-4C0D-98FB-84ADF1DAB663

Q28650557-2A6B8D62-C08A-4A1D-BE93-340EA4781971

Q28650557-3FD55E4C-EFDF-4AA8-AF85-DDFE46B9DBBF

Q28650557-6E54A551-91FC-4731-AF86-60307EFE6C8D

Q28650557-724DA875-F930-4298-BF41-0039FB3134E3

Q28650557-8763BF8F-2E0B-4699-9E0C-A4A1C00E0F7B

P304

Q28650557-8A9C5BAD-87EA-4A3B-BDC9-0C995A6E5972

P31

Q28650557-1702D120-B2FD-43F9-B5F8-8F7E06536F68

P356

Q28650557-64A61C0B-7652-495C-A0F3-137530AEE722

P407

Q28650557-48375150-9879-48C5-855F-3278F6FB063E

P433

Q28650557-15EBEA0F-61F2-46B6-9F61-674F969C6D27

P478

Q28650557-24DD9761-5AA5-4D9D-A7A2-09277AFCD2F9

P50

Q28650557-06F942B8-9ED0-4B28-960F-431B9FF6E9EB

Q28650557-154F175A-DD80-44E3-998A-3133C2E19DE5

Q28650557-42B1CE7F-E927-4FF9-BA5C-F79D41648F15

Q28650557-5D58EEDD-CB16-4D93-ACDB-8984734AC964

Q28650557-7A18E68E-E26E-4CD8-931E-3A5492BB1D34

Q28650557-F352E25F-4A6E-4FBE-8F2F-BB3E7FB79667

P577

Q28650557-819DB9DC-2935-4E40-AF4D-7526614EE9DF

P5875

Q28650557-19FF7E7F-70BA-4EA4-991B-71057C8DE6E1

P698

Q28650557-BFCB2963-890B-4EA4-A1C2-BE39810C425C

P932

Q28650557-5F9D3B14-3C62-427B-95A0-362C680CB3EC

P356

P1433

P1476

Immunogenicity of reduced dose ...... el randomised controlled trial

@en

P2093

Adam Finn

http://www.w3.org/2001/XMLSchema#string

Alison Louise Kent

http://www.w3.org/2001/XMLSchema#string

Ameneh Khatami

http://www.w3.org/2001/XMLSchema#string

Andrew J Pollard

http://www.w3.org/2001/XMLSchema#string

Catherine White

http://www.w3.org/2001/XMLSchema#string

Danielle Campbell

http://www.w3.org/2001/XMLSchema#string

David Pace

http://www.w3.org/2001/XMLSchema#string

Emma Macloed

http://www.w3.org/2001/XMLSchema#string

Jennifer McKenna

http://www.w3.org/2001/XMLSchema#string

Simon Attard-Montalto

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers

Global practices of meningococcal vaccine use and impact on invasive disease.

Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.

Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.

P304

h1554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.H1554

http://www.w3.org/2001/XMLSchema#string

P407

P433

apr01 16

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline Birks

Matthew D Snape

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274399755

http://www.w3.org/2001/XMLSchema#string

P698

25832102

http://www.w3.org/2001/XMLSchema#string

P932

4382115

http://www.w3.org/2001/XMLSchema#string